Search

Author/Creator Moosmann, Nicolas

1. FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases – The PARLIM trial (AIO KRK 0314). (September 2022)

Authors:
Modest, Dominik Paul; Karthaus, Meinolf; Kasper, Stefan; Moosmann, Nicolas; Keitel, Verena; Kiani, Alexander; Uhlig, Jens; Jacobasch, Lutz; Fischer v. Weikersthal, Ludwig; Fuchs, Martin; Kaiser, Florian; Lerchenmüller, Christian; Sent, Dagmar; Junghanß, Christian; Held, Swantje; Lorenzen, Sylvie;...
Journal:
European journal of cancer
Issue:
Volume 173(2022)
Page Start:
297
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group. Issue 1 (26th June 2012)

Authors:
Stintzing, Sebastian; Kapaun, Christine; Laubender, Rüdiger Paul; Jung, Andreas; Neumann, Jens; Modest, Dominik Paul; Giessen, Clemens; Moosmann, Nicolas; Wollenberg, Andreas; Kirchner, Thomas; Heinemann, Volker
Journal:
International journal of cancer
Issue:
Volume 132:Issue 1(2013:Jan. 01)
Page Start:
236
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗